HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Clinical trials for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS trials appear
Sign up with your email to follow new studies for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to tame aggressive lymphoma
Disease control Recruiting nowThis early-stage study tests the safety of adding two targeted drugs (polatuzumab vedotin and possibly glofitamab) to standard chemotherapy for people with untreated, fast-growing B-cell lymphoma. About 56 participants will receive the combination to see if it is tolerable and ca…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 01, 2026 15:43 UTC
-
New drug targets tough lymphomas in early trial
Disease control Recruiting nowThis study tests a drug called pidnarulex (CX-5461) in people with aggressive B-cell lymphomas that have MYC gene changes. The goal is to find a safe dose and see if it shrinks tumors. About 50 adults who have already tried other treatments will take part. This is an early-phase …
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New combo therapy shows promise for tough leukemia
Disease control Recruiting nowThis study is for adults with acute lymphoblastic leukemia (ALL), including those over 60 or unfit for standard chemo. It combines a targeted antibody-drug (inotuzumab ozogamicin) with low-intensity chemotherapy to kill cancer cells while reducing side effects. The goal is to fin…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC